CYP17 Inhibitors
4 drugsAbout CYP17
CYP17 (cytochrome P450 17A1) is a crucial enzyme in steroid hormone biosynthesis, catalyzing reactions for androgen, estrogen, and cortisol production. Its activity is essential for hormone-driven processes, making it a significant drug target.
Human genetic studies provide strong validation for CYP17 as a therapeutic target (max score 0.91), with loss-of-function variants linked to congenital adrenal hyperplasia. Activation of CYP17 is likely beneficial based on genetic evidence.
CYP17 is targeted by 4 FDA-approved small molecule drugs including ABIRATERONE ACETATE, ZYTIGA, AKEEGA and YONSA, primarily for oncology and other indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Stage III Prostate Cancer AJCC v8 with only 3 trials.
- phase1 represents biological uncertainty with 50% completion.
Human Genetic Evidence Strong
Strong genetic evidence supports CYP17's role in congenital adrenal hyperplasia (score 0.91).
High genetic support suggests that CYP17-targeting therapies have an increased probability of clinical success.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 3 traits
- • Strong signal in reproductive system or breast disease, endocrine system disease, nutritional or metabolic disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
20 totalGWAS and other genetic studies link CYP17A1 to 22 diseases.
Loss-of-function causes disease; activation may help
Loss-of-function causes disease; activation may help
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for CYP17A1 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
Three companies, Apotex, Johnson & Johnson, and Sun Pharma, have approved CYP17-targeting drugs.
The market is relatively concentrated, suggesting potential entry barriers for new companies.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| YONSA | Sun Pharma | 2018 | 1 |
Drug Modality Landscape
Modalities
Routes of Administration
CYP17 is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
Clinical Trials 272 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 91 | 45 | 21 | 25 | 68% |
| Phase 2 | 131 | 65 | 22 | 43 | 75% |
| Phase 3 | 40 | 16 | 1 | 23 | 94% |
| Phase 4 | 10 | 5 | 1 | 4 | 83% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
4 Phase 3 trials testing approved CYP17 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting CYP17. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2011 - 2023)
The first CYP17-targeting drug was approved in 2011, with the most recent in 2023.
The approval timeline indicates continued interest in CYP17 as a target, though the rate is slowing.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 4 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 4-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 8 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 178 clinical trials targeting CYP17.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities